Early pregnancy fasting plasma glucose and lipid concentrations in pregnancy and association to offspring size: a retrospective cohort study

Bin Liu, Huizhen Geng, Juan Yang, Ying Zhang, Langhui Deng, Weiqing Chen and Zilian Wang

Abstract

Background: Hyperlipidemia and high fasting plasma glucose levels at the first prenatal visit (First Visit FPG) are both related to gestational diabetes mellitus, maternal obesity/overweight and fetal overgrowth. The purpose of the present study is to investigate the correlation between First Visit FPG and lipid concentrations, and their potential association with offspring size at delivery.

Materials and methods: Pregnant women that received regular prenatal care and delivered in our center in 2013 were recruited for the study. Fasting plasma glucose levels were tested at the first prenatal visit (First Visit FPG) and prior to delivery (Before Delivery FPG). HbA1c and lipid profiles were examined at the time of OGTT test. Maternal and neonatal clinical data were collected for analysis. Data was analyzed by independent sample t test, Pearson correlation, and Chi-square test, followed by partial correlation and multiple linear regression analyses to confirm association. Statistical significance level was \( \alpha = 0.05 \).

Results: Analyses were based on 1546 mother-baby pairs. First Visit FPG was not correlated with any lipid parameters after adjusting for maternal pregravid BMI, maternal age and gestational age at First Visit FPG. HbA1c was positively correlated with triglyceride and Apolipoprotein B in the whole cohort and in the NGT group after adjusting for maternal age and maternal BMI at OGTT test. Multiple linear regression analyses showed neonatal birth weight, head circumference and shoulder circumference were all associated with First Visit FPG and triglyceride levels.

Conclusion: Fasting plasma glucose at first prenatal visit is not associated with lipid concentrations in mid-pregnancy, but may influence fetal growth together with triglyceride concentration.

Keywords: Fasting plasma glucose, Triglyceride, Gestational diabetes mellitus, Fetal growth, Lipid metabolism

Background

The intrauterine metabolic environment is of great importance for the development of offspring [1]. Gestational diabetes mellitus (GDM) is a common metabolic complication that may result in an adverse intrauterine environment and lead to fetal overgrowth [2–4], as well as short- and long-term complications for the offspring [5–8].

Hyperlipidemia, a disorder that may occur in GDM mothers [9] also contributes to the adverse intrauterine environment [10], and often occurs along with hyperglycemia [11]. Early detection of hyperlipidemia in GDM patients is of great importance. A previous study found that fasting plasma glucose (FPG) at the first prenatal visit is related to glycemic metabolism in the mid-gestational period (24–28 weeks) [12]. However, whether FPG at the first prenatal visit is associated with mid-gestational lipid metabolism has not been reported.

Recently, we reported that maternal pre-gravid BMI may influence FPG levels, and FPG at the first prenatal visit is associated with fetal growth [13]. Since maternal obesity/overweight is often complicated with hyperlipidemia [14], and hyperlipidemia may cause of fetal
overgrowth [10], we are interested in studying any possible relationship between maternal FPG, lipid metabolism and fetal growth.

In this respect, the primary purpose of the present study is to investigate the relationship between FPG at the first prenatal visit and lipid concentration in the mid-gestational stage. We also aim to examine the association of maternal FPG and lipid metabolism with neonatal birth size.

**Methods**

**Study population**

Singleton pregnant women who underwent a FPG test at the first prenatal visit (between 10 and 24 gestational weeks), received regular prenatal care (including a lipid concentration test at the time of OGTT test), and delivered in our center from January to December 2013 were recruited for the present study.

The diagnosis of GDM is based on a 75-g Oral Glucose Tolerance Test (OGTT) performed at 24-28 gestational weeks, according to the ADA criteria (fasting ≥ 5.1 mmol/L, 1 h ≥ 10.0 mmol/L, 2 h ≥ 8.5 mmol/L). Pregnant women with overt DM before pregnancy or treated with insulin during gestation were excluded in the present study. All pregnant women complicated with GDM were treated with diet.

The study has been approved by the ethical committees of the The First Affiliated Hospital of Sun Yat-sen University [Application ID: (2014)093], and all participants provided written informed consent.

**Clinical data collection**

At the first prenatal visit, maternal age, parity, the first day of the woman’s last menstrual period (LMP) and weight before pregnancy were self-reported, and maternal height was measured with a fixed stadiometer. Maternal weights at the first prenatal visit, at the time of OGTT test, and just prior to delivery were measured with a calibrated digital scale and recorded for analysis.

Gestational age was calculated from the first day of the woman’s last menstrual period (LMP) and further confirmed by early obstetric ultrasound. If the gestational age calculated from the LMP was different from that calculated by the early ultrasound, the gestational age from the early ultrasound was used [15]. In the case of in vitro fertilization, the gestational age was calculated using oocyte retrieval or co-incubation date and adding 14 days [16].

Measured neonatal parameters included birth weight, birth length, head circumference, shoulder circumference, and birthing method (vaginal vs. cesarean). Immediately following birth, the birth weight was measured with a calibrated electronic scale, birth length was measured with an infantometer, and head and shoulder circumferences were measured with a nylon tape.

**Laboratory measurements**

Fasting plasma glucose levels were measured using venous plasma obtained after at least 8 hours of fasting during the first prenatal visit and the morning following administration for delivery. A 75-g Oral Glucose Tolerance Test (OGTT) was performed between 24 and 28 gestational weeks. At the same time, maternal blood samples were also obtained for the examination of HbA1c and lipid profiles including triglyceride, cholesterol, low density lipoprotein, high density lipoprotein, apolipoprotein A1, apolipoprotein B, apolipoprotein E, and lipoprotein-a.

Plasma glucose levels were measured using a GOD-PAP kit (Human, Wiesbaden, Germany). Cholesterol and triglyceride (TG) levels were measured using an enzymatic colorimetric test kit (Human, Wiesbaden, Germany). High-density lipoprotein (HDL) and low-density lipoprotein (LDL) levels were determined by homogeneous assay using liquicolor kits (Human, Wiesbaden, Germany). Apolipoprotein A1 and Apolipoprotein B were measured with standard enzymatic assay using ApoA and ApoB kits (Human, Beckman, USA). Apolipoprotein E was examined by an immunoturbidimetry assay using APO E AUTO kit (Human, Sekisui, Japan). Lipoprotein-a was examined by a particle-enhanced turbidimetric immunoassay (PETIA) kit (Human, Diagnostic Systems, China). HbA1c was measured by high-performance liquid chromatography (HPLC) using a VARIANT II TURBO HbA1c Kit (Human, BioRad, CA, USA).

**Statistical analysis**

Data was analyzed using SPSS Version 17.0. Continuous and normal distributed variables were described as mean ± SD and analyzed by independent sample t test or Pearson correlation. Categorical variables were described as proportions and examined by Chi-square test. Partial correlations were applied to describe the relationship between maternal glucose and lipid parameters in the whole cohort, GDM and NGT groups. The false discovery rate was controlled by the Benjamini and Hochberg Method [17]. Multiple linear regression analyses were conducted to study the association between maternal glucose/lipid parameters and neonatal birth size. A p-value of 0.05 or less was considered significant.

**Results**

**Baseline characteristics of the study population**

1546 pregnant women were recruited for this study and in this cohort, eighteen pregnant women were obese (pregravid BMI ≥30 kg/m²), 174 were overweight.
(pregravid BMI: 25−29.9 kg/m²), 1261 were in normal range BMI (pregravid BMI: 18.5−24.9 kg/m²) and 90 were lean (pregravid BMI < 18.5 kg/m²). Of these women, 276 developed gestational diabetes mellitus (GDM) and 1270 were of normal glucose tolerance (NGT) during pregnancy. Pregnant women in the GDM group were older, contained more nullipara, had higher BMI prior to pregnancy, at the first prenatal visit and at the time of OGTT test compared to the NGT group, but pre-partum BMI between the groups were similar (Table 1).

Neonates of GDM mothers were born at an earlier gestational age and had a shorter birth length compared to neonates from NGT mothers. Gender of neonates, birth weight, head circumference, shoulder circumference, and route of birthing were similar between groups (Table 1). Similar maternal pre-partum BMI and neonatal birth weight between GDM and NGT groups may be a result of diet therapy for GDM pregnant women.

With respect to glucose metabolism, the GDM group had a higher fasting glucose concentration compared to the NGT group at the first prenatal visit (First Visit FPG), at OGTT test (OGTT FPG), and prior to delivery (the morning or next morning of administration for delivery, Before Delivery FPG). The GDM group also had higher HbA1c levels than the NGT group at the time of the OGTT test. Regarding lipid metabolism, triglyceride and Apolipoprotein E levels were higher in the GDM group, but no difference was observed when comparing other lipid parameters between the groups (Table 1).

**Table 1** Baseline characteristics of the research population

|                        | GDM     | NGT     | P    |
|------------------------|---------|---------|------|
| Number                 | 276     | 1270    |      |
| Age (mean ± SD)        | 31.85±4.24 | 29.42±3.82 | <0.001 |
| Parity (%)             | 0.002   |         |      |
| Nullipara (%)          | 234(84.7) | 969(76.2) |      |
| Multipara (%)          | 42(15.2)  | 301(23.7) |      |
| Maternal BMI (kg/m²)   |         |         |      |
| Before pregnancy       | 21.20±3.00 | 20.47±2.60 | <0.001 |
| At first prenatal visit| 22.60±3.26 | 21.63±2.80 | <0.001 |
| At OGTT test           | 24.46±3.09 | 23.65±2.65 | <0.001 |
| At delivery            | 25.76±3.16 | 26.04±2.87 | 0.195  |
| Fasting plasma glucose (mmol/L) |       |         |      |
| First Visit FPG        | 4.46±0.51 | 4.27±0.38 | <0.001 |
| OGTT FPG               | 4.61±0.53 | 4.27±0.31 | <0.001 |
| Before Delivery FPG    | 5.22±1.29 | 4.90±0.99 | <0.001 |
| HbA1c (%)              | 5.04±0.42 | 4.82±0.31 | <0.001 |
| HbA1c (mmol/mol)       | 31.83±6.3 | 29.37±4.32 | <0.001 |
| Lipid profile          |         |         |      |
| Triglyceride (mmol/L)  | 2.31±0.84 | 2.09±0.76 | <0.001 |
| Cholesterol (mmol/L)   | 6.09±1.02 | 6.11±0.99 | 0.754  |
| Low density lipoprotein (mmol/L) | 3.26±0.86 | 3.30±0.81 | 0.452  |
| High density lipoprotein (mmol/L) | 1.82±0.35 | 1.85±0.33 | 0.117  |
| Apolipoprotein A1 (g/L) | 2.05±0.31 | 2.01±0.34 | 0.103  |
| Apolipoprotein B (g/L)  | 0.94±0.17 | 0.94±0.18 | 0.820  |
| Apolipoprotein E (mg/L) | 48.3±13.28 | 46.6±12.67 | 0.050  |
| Lipoprotein-a (mg/L)   | 308.7±300.33 | 307.3±265.39 | 0.632 |
| Neonatal gender (%)    |         |         |      |
| Male                   | 143(51.8) | 969(76.2) |      |
| Female                 | 133(48.1) | 301(23.7) |      |
| Gestational age (day)  | 271.3±11.70 | 273.9±11.91 | <0.001 |
| Birth weight (g)       | 3105.49±496.54 | 3165.55±460.05 | 0.063 |
| Birth length (cm)      | 48.96±2.63 | 49.33±2.39 | 0.022 |
| Head circumference (cm) | 33.27±1.98 | 33.35±1.73 | 0.583 |
| Shoulder circumference (cm) | 34.33±2.52 | 34.45±2.32 | 0.482 |
| Birth method (%)       |         |         |      |
| Vaginal                | 121(43.8) | 584(45.9) |      |
| Cesarean               | 155(56.1) | 686(54) |      |

**Maternal glucose levels and lipid metabolism impact fetal growth**

Fetal growth is influenced by maternal energy metabolic status, and FPG at first prenatal visit is associated with neonatal birth weight. Therefore, we further studied the
impact of both maternal glucose and lipid concentration on fetal growth.

We conducted univariate correlations between neonatal birth weight, length, head circumference, shoulder circumference, and maternal glucose and lipid concentrations followed by partial correlations taking gestational age and pregravid BMI as confounders. In the whole cohort, neonatal birth weight, head circumference and shoulder circumference were all positively correlated with First Visit FPG, OGTT FPG, triglyceride and Apolipoprotein E, but not with other glucose or lipid parameters (Table 3). Birth length was not correlated with any glucose or lipid parameters in this research cohort.

Table 2  Partial Correlation between fasting plasma glucose, HbA1c and lipid profile

|                         | First Visit FPG | Triglyceride | Cholesterol | Low density lipoprotein | High density lipoprotein | Apolipoprotein A1 | Apolipoprotein B | Apolipoprotein E | Lipoprotein-a |
|-------------------------|-----------------|--------------|-------------|-------------------------|--------------------------|-------------------|-----------------|-----------------|--------------|
| Whole research population |                 | 0.045 0.072 0.028 | 0.046 0.003 0.012 | 0.042 0.012 0.010 | 0.010 0.026 0.013 | 0.034 0.071 0.007 | 0.037 0.029 0.071 | 0.014 0.015 0.071 |
| GDM group               |                 | 0.020 0.020 0.946 0.028 | -0.004 0.003 0.946 0.028 | 0.023 0.013 0.012 0.946 0.028 | 0.076 0.022 0.946 0.028 | -0.078 0.008 0.946 0.028 | 0.046 0.033 0.946 0.028 | 0.006 0.048 0.946 0.028 | 0.011 0.015 0.946 0.028 |
| NGT group               |                 | 0.042 0.076 0.036 | 0.062 0.016 0.886 | 0.049 0.032 0.558 | 0.014 0.039 0.485 | 0.004 0.008 0.886 | 0.029 0.085 0.032 | 0.043 0.004 0.886 | 0.019 0.010 0.886 |

Partial correlations between First Visit FPG and lipid profiles were adjusted for maternal age, pre-gravid BMI and the gestational age at the First Visit FPG. Partial correlations between HbA1c and lipid profiles were adjusted for maternal age, maternal BMI at the time of the OGTT test. All P values were corrected using the BH method (1995).

Next, we conducted a multiple linear regression analysis to investigate the association between maternal clinical characteristics (BMI, GDM), glucose/lipid parameters and neonatal birth size (birth weight, head circumference and shoulder circumference). The regression analysis showed that neonatal birth weight, head circumference and shoulder circumference were all best described by models that included First Visit FPG, triglyceride, maternal pregravid BMI and gestational age (Table 4).

Discussion

Fasting plasma glucose (FPG) at the first prenatal visit is related to the diagnosis of GDM [12], maternal pregravid BMI and neonatal birth weight [13]. Since hyperlipidemia is an important link between GDM [9], maternal obesity/overweight [18] and fetal overgrowth [10], we explored the relationship between First Visit FPG and lipid concentrations, and their potential influence on fetal growth. The result of the present study
showed that, although First Visit FPG was not correlated with any lipid parameters at mid-gestation, it was associated with neonatal birth weight, head circumference and shoulder circumference together with maternal triglyceride levels.

The crosstalk between glucose and lipid metabolism is well established [19]. During pregnancy, hyperglycemia is typically accompanied by hyperlipidemia [20] and together they promote an adverse metabolic intrauterine environment and lead to macrosomia [6]. FPG levels at the first prenatal visit is strongly correlated with glucose tolerance in mid pregnancy [12], but whether FPG levels can influence lipid metabolism is unknown.

In the present study, First Visit FPG was not correlated with any of the measured lipid parameters in mid-gestation. However, HbA1c concentration correlated with triglyceride and Apolipoprotein B levels in the NGT group. Since HbA1c concentration represents the average glucose level 2-3 months before testing [21], mid-pregnancy triglyceride and Apolipoprotein B levels would be related to earlier stage glucose metabolism. However, a single test of FPG at the first prenatal visit was not able to predict hyperlipidemia at the mid-gestational stage.

Fetal growth is influenced by maternal glucose levels [22] and lipid metabolism [23], so in the present study, we analyzed glucose and lipid factors on neonatal growth parameters. We found that maternal First Visit FPG and triglyceride levels were correlated with neonatal birth weight, head circumference and shoulder circumference.

### Table 3: Partial Correlation between maternal glycemic/lipid metabolism and neonatal birth weight, length, head circumference and shoulder circumference

| Glucose metabolism | Birth weight | Birth length | Head circumference | Shoulder circumference |
|--------------------|--------------|--------------|--------------------|------------------------|
|                     | R'  | P   | R'  | P   | R'  | P   | R'  | P   |
| First Visit FPG    | 0.098 | <0.001 | 0.047 | 0.086 | 0.071 | 0.010 | 0.084 | 0.002 |
| OGTT FPG           | 0.094 | 0.001 | 0.033 | 0.232 | 0.055 | 0.048 | 0.091 | 0.001 |
| OGTT 1hr           | 0.029 | 0.287 | -0.040 | 0.148 | 0.052 | 0.061 | 0.052 | 0.058 |
| OGTT 2hr           | 0.027 | 0.327 | 0.012 | 0.677 | 0.035 | 0.202 | 0.049 | 0.075 |
| Before Delivery FPG| 0.011 | 0.702 | -0.022 | 0.430 | -0.017 | 0.549 | 0.020 | 0.480 |
| HbA1c              | -0.013 | 0.647 | -0.026 | 0.350 | -0.024 | 0.382 | -0.019 | 0.495 |

| Lipid metabolism | Birth weight | Birth length | Head circumference | Shoulder circumference |
|------------------|--------------|--------------|--------------------|------------------------|
|                  | R'  | P   | R'  | P   | R'  | P   | R'  | P   |
| Triglyceride     | 0.100 | <0.001 | -0.003 | 0.909 | 0.094 | 0.001 | 0.120 | <0.001 |
| Cholesterol      | 0.018 | 0.518 | -0.010 | 0.710 | 0.006 | 0.815 | 0.024 | 0.378 |
| Low density lipoprotein | -0.005 | 0.843 | -0.018 | 0.526 | -0.015 | 0.578 | -0.001 | 0.979 |
| High density lipoprotein | -0.011 | 0.701 | 0.022 | 0.433 | -0.049 | 0.074 | -0.039 | 0.159 |
| Apolipoprotein A1 | -0.008 | 0.760 | -0.002 | 0.945 | -0.015 | 0.576 | -0.019 | 0.484 |
| Apolipoprotein B  | -0.016 | 0.564 | -0.032 | 0.252 | 0.008 | 0.773 | 0.028 | 0.314 |
| Apolipoprotein E  | 0.062 | 0.025 | -0.007 | 0.813 | 0.064 | 0.020 | 0.077 | 0.006 |
| Lipoprotein-a     | -0.033 | 0.235 | -0.031 | 0.262 | -0.042 | 0.129 | -0.026 | 0.342 |

All partial correlations were adjusted for gestational age and pregravid BMI.
circumference, after adjusting for gestational age and GDM. Other lipid parameters, HbA1c and after meal glucose (OGTT 1 and 2 hour) were not associated with any neonatal birth size characteristics. This result suggests that maternal fasting glucose and triglyceride concentrations play an important role in fetal growth.

The association between maternal triglyceride and neonatal birth weight has been reported in previous studies [24, 25], and our results support these studies in a much larger study population. Neonatal head circumference has been shown to be negatively correlated with low-density lipoprotein in cord plasma [26]; however, to the best of our knowledge, the positive association between maternal triglyceride and neonatal head and shoulder circumference is first described in the present study. Our recently published article found that First Visit FPG was associated with neonatal birth weight [13], and the present study revealed the association between First Visit FPG levels and neonatal head and shoulder circumference in a new research population.

There are several limitations in the present study. First of all, variation of lipid concentration is considerable during gestation [27], but we only obtained the lipid values at the time of the OGTT test. Additionally, since the BMI of most participants in the present cohort were within the normal range, the result of the present study would be applicable mainly in pregnant women with normal BMI. Further, although the present study has provided insight into the association between glucose, lipid factors and neonatal birth size, the retrospective design could be seen as another limitation. Therefore, further prospective studies measuring lipid concentrations across multiple gestational times in a wide ranging population is needed to increase validation of the result.

Conclusion
In summary, mid-pregnancy triglyceride levels are correlated with earlier stage glucose metabolism, but a single FPG test is not sufficient to predict triglyceride concentrations in the mid-gestational period. In addition, neonatal birth weight, head circumference, and shoulder circumference were all associated with maternal fasting glucose levels at the first prenatal visit and triglyceride levels at mid-gestation, but not with after-meal glucose levels at the time of OGTT test or with other lipid parameters.

Competing interests
The authors declare that they have no conflict of interest.

Authors’ contributions
BL designed the study, participated in the analysis of the data and drafted the manuscript; HG helped to draft the manuscript; JY, YZ and LD participated in its design and acquired the data; WC analyzed the data; ZW critically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The present study is funded by the Sun Yat-sen University Clinical Research 5010 Program (to Zilian Wang) and National Natural Science Foundation of China (to Bin Liu).

Grant
The present study is funded by Sun Yat-sen University Clinical Research 5010 Program (No. 201204, to Zilian Wang) and National Natural Science Foundation of China (No. 81300493, to Bin Liu).

Author details
1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Road II, Guangzhou 510080, PR China. 2Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, PR China. 3Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.

Received: 25 November 2015 Accepted: 11 March 2016
Published online: 17 March 2016

References
1. Catalano PM. The impact of gestational diabetes and maternal obesity on the mother and her offspring. J Dev Orig Health Dis. 2010;1(4):208–15.
2. Surkan PJ, Hsieh CC, Johannsson AL, Dickman PW, Cnattingius S. Reasons for increasing trends in large for gestational age births. Obstet Gynecol. 2004; 104(4):720–6.
3. Josipovic L, Petitt DJ. Gestational diabetes mellitus. JAMA. 2001;285(20):2516–8.
4. Ananth CV, Wen SW. Trends in fetal growth among singleton gestations in the United States and Canada, 1985 through 1998. Semin Perinatol. 2002; 26(4):260–7.
5. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Launbjerg J, Damm P. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care. 2008;31(2):340–6.
6. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Launbjerg J, Schmidt L, Damm P. Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab. 2009;94(7):2464–70.
7. Kim SY, England JL, Sharma JA, Njorge T. Gestational diabetes mellitus and risk of childhood overweight and obesity in offspring: a systematic review. Exp Diabetes Res. 2011;2011:541308.
8. Mccullen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev. 2005;85(2):571–633.
9. Mizak I, Arfa A, Felikh M, Debbabi H, Bouslama A, Boumaiza I, Azouali M, Khan NA, Tabka Z. Inflammation and impaired endothelium-dependant vasodilatation in non obese women with gestational diabetes mellitus: preliminary results. Lipids Health Dis. 2013;12:93.
10. Ólímpos PR, Rigotti A, Busso D, Berkowitz L, Santos JL, Borzone GR, Poblete JA, Vera C, Belmar C, Goldenberg D. Maternal hypertriglyceridemia: A link between maternal overweight-obesity and macrosomia in gestational diabetes. Obesity. 2014;22(10):2156–63.
11. Solomon CG, Willett WC, Carey VJ, Rich-Edwards J, Hunter DJ, Colditz GA, Stampfer MJ, Speizer FE, Spiegelman D, Manson JE. A prospective study of prediabetic determinants of gestational diabetes mellitus. JAMA. 1997;278(13):1078–83.
12. Zhu WW, Yang HX, Wei YM, Yan J, Wang ZL, Li XL, et al. Evaluation of the Value of Fasting Plasma Glucose in First Prenatal Visit to Diagnose Gestational Diabetes Mellitus in China. Diabetes Care. 2012.
13. Liu B, Chen H, Xu Y, An C, Zhong L, Wang X, Zhang Y, Chen H, Zhang J, Wang Z. Fetal Growth Is Associated with Maternal Fasting Plasma Glucose at First Prenatal Visit. PLoS One. 2014;9(12), e116352.
14. Yessoufou A, Moutairou K. Maternal diabetes in pregnancy: early and long-term outcomes on the offspring and the concept of “metabolic memory”. Exp Diabetes Res. 2011;2011:218598.
15. Hunter LA. Issues in pregnancy dating: revisiting the evidence. J Midwifery Women’s Health. 2009;54(3):184–90.
16. Tunon K, Ek-Nes SH, Grottum P, Von Duing V, Kahn JA. Gestational age in pregnancies conceived after in vitro fertilization: a comparison between age assessed from oocyte retrieval, crown-rump length and biparietal diameter. Ultrasound Obstet Gynecol. 2000;15(1):41–6.
17. Benjamini Y, Hochberg Y. Controlling The False Discovery Rate - A Practical And Powerful Approach To Multiple Testing. J R Stat Soc. 1995;57:289–300.
18. King JC. Maternal obesity, metabolism, and pregnancy outcomes. Annu Rev Nutr. 2006;26:271–91.
19. Lu B, Bridges D, Yang Y, Fisher K, Cheng A, Chang L, Meng ZX, Lin JD, Downes M, Yu RT. Metabolic crosstalk: molecular links between glycogen and lipid metabolism in obesity. Diabetes. 2014;63(9):2935–48.
20. Farren M, Daly N, O’Higgins AC, McKeating A, Maguire PJ, Turner MJ. The interplay between maternal obesity and gestational diabetes mellitus. J Perinat Med. 2015;43(3):311–7.
21. Bennett CM, Guo M, Dharmage SC. HbA1c as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet Med. 2007;24(4):333–43.
22. Scholl TO, Sowers M, Chen X, Lenders C. Maternal glucose concentration influences fetal growth, gestation, and pregnancy complications. Am J Epidemiol. 2001;154(6):514–20.
23. Langer O, Yogev Y, Xenakis EM, Brustman L. Overweight and obese in gestational diabetes: the impact on pregnancy outcome. Am J Obstet Gynecol. 2005;192(6):1768–76.
24. Di Cianni G, Miccoli R, Volpe L, Lencioni C, Ghio A, Giovannitti MG, Cuccuru I, Pellegrini G, Chatzianagnostou K, Boldrini A. Maternal triglyceride levels and newborn weight in pregnant women with normal glucose tolerance. Diabet Med. 2005;22(1):21–5.
25. Whyte K, Kelly H, O’Dwyer V, Gibbs M, O’Higgins A, Turner MJ. Offspring birth weight and maternal fasting lipids in women screened for gestational diabetes mellitus (GDM). Eur J Obstet Gynecol Reprod Biol. 2013;170(1):67–70.
26. Ophir E, Oettinger M, Nisimov J, Hirsch Y, Fait V, Dourleshter G, Shnaider O, Snitkovsky T, Bornstein J. Cord blood lipids concentrations and their relation to body size at birth: possible link between intrauterine life and adult diseases. Am J Perinatol. 2004;21(1):35–40.
27. Butter NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr. 2000;71(5 Suppl):1265–615.